副甲狀腺功能低下症治療市場 - 按產品類型（補充劑 [鈣、維生素 D、鎂、鋅]、副甲狀腺素）、給藥途徑（口服、腸胃外）、配銷通路（醫院藥房、零售藥房）與預測，2024 年- 2032 年

Hypoparathyroidism Treatment Market - By Product Type (Supplements [Calcium, Vitamin D, Magnesium, Zinc], Parathyroid Hormone), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) & Forecast, 2024 - 2032

出版日期: 2024年02月28日 | 出版商:

Global Market Insights Inc. | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於人們對治療選擇的認知不斷提高、醫療保健技術進步以及老年人口不斷增加，預計 2024 年至 2032 年甲狀旁腺功能減退症治療市場規模將以 6.9% 的複合年成長率成長。副甲狀腺功能減退症的盛行率日益增加是推動市場成長的主要驅動力。副甲狀腺功能減退症的特徵是副甲狀腺素 (PTH) 水平異常低，影響全球很大一部分人口。

根據 Medscape.com 2022 年的數據，原發性副甲狀腺功能亢進症在女性中的盛行率較高，發生率為每 10 萬人年 66 例，而男性為每 10 萬人年 25 例。遺傳傾向、自體免疫疾病、涉及甲狀腺或副甲狀腺的手術干預以及其他潛在的醫療狀況等因素導致副甲狀腺功能減退症發病率上升。隨著醫療保健專業人員和一般大眾對這種內分泌失調的認知不斷提高，該疾病的診斷和治療也相應增加。確診病例的激增使得對有效治療方案的需求相應增加。因此，製藥公司和醫療保健提供者正在投資研發工作，以引入創新療法並改善現有的治療方式，從而促進市場成長。

副甲狀腺功能低下症治療產業按產品類型、給藥途徑、配銷通路和地區細分。

預計到2032 年，副甲狀腺素(PTH) 產品類型細分市場的市佔率將以7.2% 的速度成長。標準。這些療法透過補充體內缺乏的 PTH 水平來發揮作用，從而恢復鈣和磷酸鹽平衡並進一步促進節段生長。

按配銷通路，零售藥房領域的甲狀旁腺功能減退症治療市場從2024年到2032年將錄得6.4%的複合年成長率，因為它們為甲狀旁腺功能減退症患者提供了方便的藥物獲取。零售藥局提供多種副甲狀腺功能減退症治療選擇，包括處方藥和非處方補充劑，使其成為尋求定期補充和諮詢的患者的首選。零售藥局提供的便利性和可近性也將有助於它們在副甲狀腺功能減退症治療藥物的分銷中日益突出。

在醫療保健支出增加、副甲狀腺功能減退症盛行率不斷上升以及對該疾病及其管理認知不斷提高的推動下，到2032 年，亞太地區甲狀旁腺功能減退症治療行業將以7.4% 的複合年成長率獲得顯著成長。旨在改善醫療基礎設施和擴大基本藥物取得範圍的政府措施進一步推動了中國、印度和日本等國家的市場成長。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 中東和非洲其他地區

第 9 章：公司簡介

Ascendis Pharma A/S
Amgen Inc.
BioNTech SE
Bristol-Myers Squibb Company
Entera Bio Ltd.
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
SK biopharmaceuticals Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited.

簡介目錄

Product Code: 8302

Hypoparathyroidism Treatment Market size is expected to grow at 6.9% CAGR during 2024-2032, driven by growing awareness about treatment options, technological advancements in healthcare, and rising geriatric population. The increasing prevalence of hypoparathyroidism is a primary driver propelling the market growth. Hypoparathyroidism, characterized by abnormally low levels of parathyroid hormone (PTH), affects a substantial portion of the global population.

As per Medscape.com in 2022, primary hyperparathyroidism exhibited a higher prevalence among women, with an incidence of 66 per 100,000 person-years, compared to 25 per 100,000 person-years in males. Factors, such as genetic predisposition, autoimmune disorders, surgical interventions involving the thyroid or parathyroid glands, and other underlying medical conditions are contributing to the rising incidence of hypoparathyroidism. As awareness about this endocrine disorder grows among healthcare professionals and the general population, there is a corresponding increase in the diagnosis and treatment of the condition. This surge in diagnosed cases necessitates a corresponding rise in the demand for effective treatment options. Consequently, pharmaceutical companies and healthcare providers are investing in R&D efforts to introduce innovative therapies and improve existing treatment modalities, adding to the market growth.

The hypoparathyroidism treatment industry is segmented into product type, route of administration, distribution channel and region.

The market share from the parathyroid hormone (PTH) product type segment is anticipated to register 7.2% growth rate till 2032. PTH replacement therapy, such as synthetic PTH analogs, is considered the gold standard treatment for hypoparathyroidism. These therapies work by replenishing the deficient levels of PTH in the body, thereby restoring calcium and phosphate balance and further enhancing the segment growth.

By distribution channel, the hypoparathyroidism treatment market from the retail pharmacy segment will record 6.4% CAGR from 2024 to 2032, as they provide convenient access to medications for patients suffering from hypoparathyroidism. Retail pharmacies offer a wide range of hypoparathyroidism treatment options, including prescription medications and over-the-counter supplements, making them a preferred choice for patients seeking regular refills and consultations. The convenience and accessibility offered by retail pharmacies will also contribute to their growing prominence in the distribution of hypoparathyroidism treatments.

Asia Pacific hypoparathyroidism treatment industry is set to gain prominence at 7.4% CAGR till 2032, driven by increasing healthcare expenditure, growing prevalence of hypoparathyroidism, and rising awareness about the condition and its management. Government initiatives aimed at improving healthcare infrastructure and expanding access to essential medications are further fueling the market growth in countries like China, India, and Japan.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing parathyroid disorders
  - 3.2.1.2 Increasing government initiatives
  - 3.2.1.3 Rising technological advancements
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Associated side effects
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Supplements
- 5.2.1 Calcium supplements
- 5.2.2 Vitamin D supplements
- 5.2.3 Other supplements
  - 5.2.3.1 Magnesium
  - 5.2.3.2 Zinc
5.3 Parathyroid hormone

Chapter 6 Market Estimates and Forecast,By Route of Administration 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacy
7.3 Retail pharmacy
7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 Rest of Middle East & Africa